Radiopharm Reports 93.5% MRI Agreement for RAD101 in Interim Phase 2b Brain Metastases Study

By Public Technologies
  • Radiopharm Theranostics presented interim Phase 2b RAD101 brain metastases imaging results at the Society for Neuro-Oncology meeting, held November 12-15, 2026.
  • Results showed strong agreement with MRI in detecting suspected recurrence following radiotherapy, with preliminary evidence of diagnostic sensitivity.
  • No serious treatment-emergent adverse events occurred among 32 participants; final diagnostic accuracy analyses are expected in Q1 2027.
  • FDA alignment supports a single, multicenter Phase 3 imaging trial evaluating RAD101 in patients with indeterminate brain metastases following radiotherapy.
  • Siemens Healthineers will manufacture and distribute RAD101 doses for the planned US registrational trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160800PRIMZONEFULLFEED1001303707) on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.